1
|
Yáñez U, Álvarez J, Lorenzo G, Caínzos J, Dubuc J, Becerra JJ, Herradón PG, Peña AI, Quintela LA. Effect of recombinant bovine granulocyte colony-stimulating factor treatment during the peripartum period on postpartum diseases, reproductive performance, and milk production in Holstein cattle. Res Vet Sci 2024; 177:105368. [PMID: 39098094 DOI: 10.1016/j.rvsc.2024.105368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Revised: 07/18/2024] [Accepted: 07/29/2024] [Indexed: 08/06/2024]
Abstract
To boost the immune function around parturition, recombinant bovine granulocyte colony-stimulating factor (rbG-CSF) has been used to increase the number of neutrophils. Therefore, the aim of this study was to quantify the effect of rbG-CSF administration on the incidence of postpartum pathologies, reproductive performance, and milk production during the first three months of lactation. A total of 199 Holstein cows from one herd were included and were randomly allocated into two groups: Control (n = 103) and rbG-CSF (n = 96). Cows in the rbG-CSF group received 2 doses of a rbG-CSF injectable formulation, one 7 days before the expected date of calving and the other within 24 h after calving. For 6 weeks following calving, animals were examined weekly to assess the presence of postpartum pathologies. Milk production, protein and fat content, and somatic cell count were determined monthly by the regional dairy herd improvement association. Data about the reproductive performance were collected from on-farm software. To analyse the effect of treatment on the incidence of postpartum pathologies, Pearson's χ2 test and multivariable logistic regressions were performed. The effect on reproductive performance was analysed using Cox proportional hazard regression analysis for days open, binary logistic regression for first service conception rate and Oneway ANOVA test for the number of artificial inseminations. The effects of treatment on milk yield and milk composition were checked using GLM repeated measures analysis. No statistically significant differences were observed between treatment groups for any of the parameters evaluated. Only parity had a significant effect on days open and milk production (p < 0.05). In conclusion, in the present study no evidence was found that rbG-CSF could have an effect on the reproductive and productive parameters evaluated.
Collapse
Affiliation(s)
- Uxía Yáñez
- Unit of Reproduction and Obstetrics, Dept. of Animal Pathology, Universidade de Santiago de Compostela, Faculty of Veterinary Medicine, Avda. Carballo Calero s/n, 27002 Lugo, Spain.
| | - Jacobo Álvarez
- Unit of Reproduction and Obstetrics, Dept. of Animal Pathology, Universidade de Santiago de Compostela, Faculty of Veterinary Medicine, Avda. Carballo Calero s/n, 27002 Lugo, Spain.
| | | | - Juan Caínzos
- ABS Progenex, Calle Calidad 34, 28906 Getafe, Spain.
| | - Jocelyn Dubuc
- Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec J2S 2M2, Canada.
| | - Juan J Becerra
- Unit of Reproduction and Obstetrics, Dept. of Animal Pathology, Universidade de Santiago de Compostela, Faculty of Veterinary Medicine, Avda. Carballo Calero s/n, 27002 Lugo, Spain.
| | - Pedro G Herradón
- Unit of Reproduction and Obstetrics, Dept. of Animal Pathology, Universidade de Santiago de Compostela, Faculty of Veterinary Medicine, Avda. Carballo Calero s/n, 27002 Lugo, Spain.
| | - Ana I Peña
- Unit of Reproduction and Obstetrics, Dept. of Animal Pathology, Universidade de Santiago de Compostela, Faculty of Veterinary Medicine, Avda. Carballo Calero s/n, 27002 Lugo, Spain.
| | - Luis A Quintela
- Unit of Reproduction and Obstetrics, Dept. of Animal Pathology, Universidade de Santiago de Compostela, Faculty of Veterinary Medicine, Avda. Carballo Calero s/n, 27002 Lugo, Spain.
| |
Collapse
|
2
|
Strickland JM, Leite de Campos J, Gandy J, Mavangira V, Ruegg PL, Sordillo L. A randomized control trial to test the effect of pegbovigrastim treatment at dry-off on plasma and milk oxylipid profiles during early mammary gland involution and the postparturient period. J Dairy Sci 2024; 107:5070-5089. [PMID: 38246537 DOI: 10.3168/jds.2023-23879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 12/18/2023] [Indexed: 01/23/2024]
Abstract
The early period of mammary gland involution is a critical juncture in the lactation cycle that can have significant effects on milk production and mammary gland health. Pegbovigrastim (PEG) administered 1 wk prior and on the day of parturition can enhance immune function and reduce the incidence of mastitis in the early postpartum period. Oxylipids are potent metabolites of polyunsaturated fatty acids (PUFA) and are important mediators of inflammation. The objective of this study was to evaluate effects of PEG given 1 wk before and at the day of dry-off (D0) on concentrations of oxylipids in plasma and milk from 7 d before D0 to 14 d after, as well as the effects during the first 14 d of the subsequent lactation. We hypothesized that both pro- and anti-inflammatory oxylipids would vary based on initiation of mammary gland involution and that pegbovigrastim would affect oxylipid concentrations, particularly those related to leukocytes. A complete randomized blocked design was used to enroll cows into either a PEG treatment group (n = 10) or control group (n = 10; CON). Blood samples were collected -7, -2, -1, 0, 1, 2, 4, 7, and 14 d relative to dry-off and 5, 10, and 14 d postcalving. Samples were analyzed for PUFA and oxylipids in milk and plasma by ultra-performance mass spectrometry and liquid chromatography tandem quadrupole mass spectrometry, respectively. Overall, 30 lipid mediators were measured in both milk and plasma. Repeated measures analyses revealed a significant interaction of treatment by time for milk 8-iso-keto-15-prostaglandin E2, prostaglandin F2α, plasma 8,12-iso-prostaglandin Fα-VI, 11-hydroxyeicosatetraenoic acid, and 12-hydroxyheptadecatienoic acid. The majority of milk PUFA and oxylipids differed significantly during early mammary gland involution and into the early postpartum period. This study demonstrated changes in oxylipids in milk secretions and plasma during early involution, and further investigation may illuminate multiple complex processes and reveal targets for optimization of mammary gland involution.
Collapse
Affiliation(s)
- Jaimie M Strickland
- College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824.
| | - Juliana Leite de Campos
- College of Agriculture and Natural Resources, Animal Science, Michigan State University, East Lansing, MI 48824
| | - Jeff Gandy
- College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824
| | - Vengai Mavangira
- College of Veterinary Medicine, Iowa State University, Ames, IA 50011
| | - Pamela L Ruegg
- College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824
| | - Lorraine Sordillo
- College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824
| |
Collapse
|
3
|
Barca J, Schukken YH, Meikle A, Chilibroste P, Bouman M, Hogeveen H. Pegbovigrastim treatment resulted in an economic benefit in a large randomized clinical trial in grazing dairy cows. J Dairy Sci 2023; 106:1233-1245. [PMID: 36460504 DOI: 10.3168/jds.2022-21974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 08/31/2022] [Indexed: 11/30/2022]
Abstract
This randomized controlled trial on 4 commercial grazing dairy farms investigated whether pegbovigrastim (PEG) treatment affected partial net return as calculated from milk revenues and costs for feed, medical treatments [clinical mastitis, uterine disease, and other diseases (i.e., any medical treatment that was not intended for clinical mastitis or uterine disease)], inseminations, and culling during a full lactation in grazing dairy cows. We also explored the effect of potential interactions of PEG treatment with parity, prepartum body condition score, and prepartum nonesterified fatty acids concentration on partial net return, milk revenues, and the costs mentioned above. Holstein cows were randomly assigned to 1 of the 2 following trial arms: a first PEG dose 9.4 ± 0.3 (mean ± standard error) days before the calving date and a second dose within 24 hours after calving (PEG: primiparous = 342; multiparous = 697) compared with untreated controls (control: primiparous = 391; multiparous = 723). The effect of PEG treatment on the outcomes of interest expressed per year was tested using general linear mixed models. Results are presented as least squares means ± standard error. Overall, PEG treatment increased the partial net return, resulting in an economic benefit per cow per year of $210 ± 100. The cost of treatment of clinical mastitis was lower for PEG treated cows compared with control cows ($9 ± 3). The largest nonsignificant difference was seen for the cost of culling; additionally, PEG treatment numerically reduced the cost of culling by $145 ± 77.
Collapse
Affiliation(s)
- Joaquín Barca
- Department of Dairy Science and Technology, Veterinary Faculty, Universidad de la República, 12100, Montevideo, Uruguay; Preventive Medicine and Epidemiology, Veterinary Faculty, Universidad de la República, 12100, Montevideo, Uruguay; Department of Animal Sciences, Wageningen University, 6700 AA, Wageningen, the Netherlands.
| | - Ynte H Schukken
- Department of Animal Sciences, Wageningen University, 6700 AA, Wageningen, the Netherlands; Royal GD, Deventer, 7400 AA, the Netherlands
| | - Ana Meikle
- Animal Endocrine and Metabolism Laboratory, Veterinary Faculty, Universidad de la República, Montevideo, 12100, Uruguay
| | - Pablo Chilibroste
- Animal Production and Pasture, Agronomy Faculty, Universidad de la República, Paysandú, 60000, Uruguay
| | - Mette Bouman
- Veterinary Practitioner, Colonia, 70400, Uruguay
| | - H Hogeveen
- Business Economics group, Wageningen University & Research, 6706 KN, Wageningen, the Netherlands
| |
Collapse
|
4
|
Evaluation of mammary gland health in dairy cows treated by pegylated granulocyte colony-stimulating factor. ACTA VET BRNO 2023. [DOI: 10.2754/avb202392010003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The study aimed to determine the effect of the treatment by pegbovigrastim on the health of the mammary gland in dairy cows. Experimental animals were successively treated with 15 mg of pegylated bovine granulocyte colony-stimulating factor (bG-CSF, pegbovigrastim, PEG, Imrestor, Elanco) 10 ± 3 days before expected parturition and 1 day after actual parturition. Cows in the control group remained without treatment. The occurrence of clinical and subclinical mastitis in dairy cows during the first three months postpartum, and bacteriological findings in milk and milk yield were evaluated after preventive pegbovigrastim treatment. The influence of pegbovigrastim, as an additional treatment of mastitis caused by Streptococcus uberis in dairy cows on the standard course of treatment, was evaluated. The average number of antimicrobial (AML) interventions necessary for healing, the proportion of cows with 1, 2, 3 and more AML interventions, milk somatic cell count before treatment, 1 and 2 months after treatment and average milk withdrawal time were evaluated between groups. The results of the study did not find positive effects of pegbovigrastim on any evaluated variables.
Collapse
|
5
|
Lippolis JD, Putz EJ, Reinhardt TA, Casas E, Weber WJ, Crooker BA. Effect of Holstein genotype on immune response to an intramammary Escherichia coli challenge. J Dairy Sci 2022; 105:5435-5448. [DOI: 10.3168/jds.2021-21166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 03/08/2022] [Indexed: 11/19/2022]
|
6
|
Mestav B. Assessment of the relationship between the postpartum diseases susceptibility and the bovine monocyte subsets via Bayesian logistic regression, under various prior distributions. Res Vet Sci 2022; 145:1-12. [DOI: 10.1016/j.rvsc.2022.01.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 01/21/2022] [Accepted: 01/24/2022] [Indexed: 10/19/2022]
|
7
|
An overview on mastitis-associated Escherichia coli: Pathogenicity, host immunity and the use of alternative therapies. Microbiol Res 2021; 256:126960. [PMID: 35021119 DOI: 10.1016/j.micres.2021.126960] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/26/2021] [Accepted: 12/27/2021] [Indexed: 12/11/2022]
Abstract
Escherichia coli is one of the leading causes of bovine mastitis; it can cause sub-clinical, and clinical mastitis characterized by systemic changes, abnormal appearance of milk, and udder inflammation. E. coli pathogenicity in the bovine udder is due to the interaction between its virulence factors and the host factors; it was also linked to the presence of a new pathotype termed mammary pathogenic E. coli (MPEC). However, the presence of this pathotype is commonly debated. Its main virulence factor is the lipopolysaccharide (LPS) that is responsible for causing an endotoxic shock, and inducing a strong immune response by binding to the toll-like receptor 4 (TLR4), and stimulating the expression of chemokines (such as IL-8, and RANTES) and pro-inflammatory cytokines (such as IL-6, and IL-1β). This strong immune response could be used to develop alternative and safe approaches to control E. coli causing bovine mastitis by targeting pro-inflammatory cytokines that can damage the host tissue. The need for alternative treatments against E. coli is due to its ability to resist many conventional antibiotics, which is a huge challenge for curing ill animals. Therefore, the aim of this review was to highlight the pathogenicity of E. coli in the mammary gland, discuss the presence of the new putative pathotype, the mammary pathogenic E. coli (MPEC) pathotype, study the host's immune response, and the alternative treatments that are used against mastitis-associated E. coli.
Collapse
|
8
|
Barca J, Meikle A, Bouman M, Schukken YH. Effect of pegbovigrastim on fertility and culling in grazing dairy cows and its association with prepartum nonesterified fatty acids. J Dairy Sci 2021; 105:710-725. [PMID: 34763910 DOI: 10.3168/jds.2021-20785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 09/14/2021] [Indexed: 11/19/2022]
Abstract
This randomized controlled trial on 4 commercial grazing dairy farms investigated whether treatment with pegbovigrastim (PEG) affected fertility and culling as measured during the full lactation. We also explored the effect of potential interactions of PEG treatment with parity, prepartum body condition score, prepartum nonesterified fatty acid concentration (pre-NEFA), and early-lactation clinical disease on these outcomes. Holstein cows were randomly assigned to 1 of 2 trial arms: a first PEG dose approximately 7 d before the expected calving date and a second dose within 24 h after calving (PEG: primiparous = 342; multiparous = 697) compared with untreated controls (control: primiparous = 391; multiparous = 723). Cox's proportional hazards regression models were used to analyze rate of first insemination, rate of pregnancy [within 150 and 305 d in milk (DIM)], and hazard of culling. Additional analyses were performed on data that were stratified by parity group and pre-NEFA class (low ≤0.3; high >0.3 mM). In high pre-NEFA cows, PEG treatment increased the rate of first insemination [hazard ratio (HR) = 1.15]. Early-lactation clinical mastitis (CM) and uterine disease (UD: retained placenta, metritis, or both) were associated with a reduced rate of pregnancy within 150 DIM (HR = 0.49 and 0.78, respectively). Pegbovigrastim treatment in high pre-NEFA cows with CM and UD increased the rate of pregnancy within 150 DIM (HR = 1.75 and 1.46, respectively). In high pre-NEFA cows, PEG treatment resulted in a lower hazard of culling (HR = 0.79). No treatment effect was detected in low pre-NEFA cows. This study shows that the effect of PEG treatment on fertility and culling interacts with pre-NEFA. In high pre-NEFA cows, PEG treatment increased the rate of first insemination, counteracted the negative association of early-lactation CM and UD with the rate of pregnancy, and decreased the hazard of culling.
Collapse
Affiliation(s)
- Joaquín Barca
- Department of Dairy Science and Technology, Veterinary Faculty, Universidad de la República, Montevideo, 11600, Uruguay; Department of Animal Sciences, Wageningen University, Wageningen, 6700 AH, the Netherlands.
| | - Ana Meikle
- Animal Endocrine and Metabolism Laboratory, Veterinary Faculty, Universidad de la República, Montevideo, 11600, Uruguay
| | - Mette Bouman
- Veterinary Practitioner, Colonia, 70400, Uruguay
| | - Ynte H Schukken
- Department of Animal Sciences, Wageningen University, Wageningen, 6700 AH, the Netherlands; Royal GD, Deventer, 7400 AA, the Netherlands
| |
Collapse
|
9
|
Crookenden MA, Roche JR, Heiser A, Kuhn-Sherlock B, Higham CD, Phyn CVC, Turner SA. Effect of dose rate and timing of administration of pegbovigrastim on white blood cell responses in grazing dairy cows. J Dairy Sci 2021; 104:11955-11972. [PMID: 34419282 DOI: 10.3168/jds.2021-20630] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 06/29/2021] [Indexed: 11/19/2022]
Abstract
Transition dairy cows experience a decline in immune function that increases the risk of peripartum disease. One strategy to improve peripartum immune function involves the use of a commercially available cytokine: bovine granulocyte-colony stimulating factor, with the addition of polyethylene glycol to increase duration of effectiveness. Treatment with Imrestor (15 mg pegbovigrastim; Elanco) one week before expected calving date (d -7) and again on the day of calving (d 0) was previously reported to increase the neutrophil number and improve neutrophil function; as a result, the incidence of clinical mastitis was reduced. We conducted 2 experiments over consecutive years to investigate the effect of a lower dose rate (half or quarter dose rate) of Imrestor in grazing dairy cattle and reduced administration frequency: one dose instead of the recommended 2. White blood cell counts were measured to determine changes in relative cell populations in response to treatment. Neutrophil function was assessed by measuring myeloperoxidase activity. Imrestor treatment increased the numbers of neutrophils, band cells, lymphocytes, and monocytes until 14 d postcalving in a dose-dependent manner; it also increased neutrophil myeloperoxidase activity. One dose of Imrestor increased white blood cell counts and myeloperoxidase activity, but the timing, degree, and duration of the response were different relative to the recommended 2 doses and were also dependent upon when Imrestor treatment was given. One dose at d -7 relative to expected calving date did not have a lasting effect postcalving, whereas one dose only on d 0 caused a delayed effect relative to cows that received 2 doses. There was no effect of Imrestor on milk yield or on blood indicators of transition cow health. A lower dose rate of Imrestor or a single dose of Imrestor on the day of calving may be sufficient to improve neutrophil function during the early postpartum in grazing dairy cows. Large-scale field studies are required to determine whether the smaller response from lower dose rates or the timing of the immunological response to drug delivery affect animal health in early lactation.
Collapse
Affiliation(s)
- M A Crookenden
- DairyNZ Ltd., Private Bag 3221, Hamilton 3240, New Zealand; Hopkirk Research Institute, AgResearch, Palmerston North 4442, New Zealand.
| | - J R Roche
- DairyNZ Ltd., Private Bag 3221, Hamilton 3240, New Zealand
| | - A Heiser
- Hopkirk Research Institute, AgResearch, Palmerston North 4442, New Zealand
| | | | - C D Higham
- DairyNZ Ltd., Private Bag 3221, Hamilton 3240, New Zealand
| | - C V C Phyn
- DairyNZ Ltd., Private Bag 3221, Hamilton 3240, New Zealand
| | - S-A Turner
- DairyNZ Ltd., Private Bag 3221, Hamilton 3240, New Zealand
| |
Collapse
|
10
|
Barca J, Meikle A, Bouman M, Gnemmi G, Ruiz R, Schukken YH. Effect of pegbovigrastim on clinical mastitis and uterine disease during a full lactation in grazing dairy cows. PLoS One 2021; 16:e0252418. [PMID: 34043727 PMCID: PMC8158865 DOI: 10.1371/journal.pone.0252418] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 05/17/2021] [Indexed: 11/18/2022] Open
Abstract
In this randomized controlled trial on four commercial grazing dairy farms, we investigated whether pegbovigrastim (PEG) treatment affects clinical mastitis (CM) and uterine disease (i.e. retained placenta (RP), metritis and endometritis) occurrence during a full lactation. The association of prepartum body condition score and prepartum non-esterified fatty acid (NEFA) concentration with disease occurrence was also evaluated. Holstein cows were randomly assigned to one of two treatments: first PEG dose approximately 7 d before the expected calving date and a second dose within 24 h after calving (PEG) compared to untreated controls (Control). In total, 2,153 animals were included in the study: 733 primiparous cows (Control = 391, PEG = 342) and 1420 multiparous cows (Control = 723, PEG = 697). Treatment effects were evaluated with generalized linear mixed models and Cox's proportional hazard models. Treatment with PEG reduced the occurrence of a first case of CM during the first 30 days in milk (DIM) by 24.6% and reduced the hazard of a first case and the rate of total cases of CM during the full lactation. All PEG treatment effects were independent of parity. Prepartum body condition score interacted with PEG treatment: in over-conditioned cows, PEG reduced the occurrence of a first case of CM during the first 30 DIM by 49.5%. The hazard analysis of a first case of CM during the full lactation suggested that the preventive effect of PEG disappeared with increasing DIM. Treatment with PEG did not affect the occurrence of RP or metritis. Pegbovigrastim treated cows with metritis subsequently showed a reduced occurrence of endometritis compared to control cows with metritis. Pegbovigrastim reduces the occurrence of CM particularly in cows at risk of elevated lipid mobilization, and PEG ameliorates the uterine healing process in cows that experienced metritis.
Collapse
Affiliation(s)
- Joaquín Barca
- Department of Dairy Science and Technology, Veterinary Faculty, Montevideo, Uruguay
- Department of Animal Sciences, Wageningen University, Wageningen, the Netherlands
- * E-mail:
| | - Ana Meikle
- Animal Endocrine and Metabolism Laboratory, Veterinary Faculty, Montevideo, Uruguay
| | | | - Giovanni Gnemmi
- Bovinevet Internacional Bovine Ultrasound Services & Herd Management, Huesca, Spain
- Department of Animal Reproduction Veterinary Faculty, Catholic University of Valencia, Valencia, Spain
| | | | - Ynte H. Schukken
- Department of Animal Sciences, Wageningen University, Wageningen, the Netherlands
- GD Animal Health, Deventer, the Netherlands
| |
Collapse
|
11
|
Manandhar M, Chun E, Romesberg FE. Genetic Code Expansion: Inception, Development, Commercialization. J Am Chem Soc 2021; 143:4859-4878. [DOI: 10.1021/jacs.0c11938] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Miglena Manandhar
- Synthorx, a Sanofi Company, La Jolla, California 92037, United States
| | - Eugene Chun
- Synthorx, a Sanofi Company, La Jolla, California 92037, United States
| | | |
Collapse
|
12
|
Putz EJ, Palmer MV, Ma H, Casas E, Reinhardt TA, Lippolis JD. Case report: characterization of a persistent, treatment-resistant, novel Staphylococcus aureus infection causing chronic mastitis in a Holstein dairy cow. BMC Vet Res 2020; 16:336. [PMID: 32933523 PMCID: PMC7491080 DOI: 10.1186/s12917-020-02528-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 08/18/2020] [Indexed: 12/21/2022] Open
Abstract
Background Mastitis is the most common health concern plaguing the modern dairy cow and costs dairy producers estimates of two billion dollars annually. Staphylococcus aureus infections are prevalent, displaying varied disease presentation and markedly low cure rates. Neutrophils are considered the first line of defense against mastitis causing bacteria and are frequently targeted in the development of treatment and prevention technologies. We describe a case of naturally occurring, chronic mastitis in a Holstein cow (1428), caused by a novel strain of S. aureus that was not able to be cleared by antibiotic treatment. Case presentation The infection was identified in a single quarter, 2 months into the cow’s first lactation. The infection persisted for the following 20 months, including through dry off, and a second calving and lactation. This case of mastitis was associated with a consistently high somatic cell count, however presented with no other clinical signs. This cow was unsuccessfully treated with antibiotics commonly used to treat mastitis, consisting of two rounds of treatment during lactation and an additional round at the beginning of dry off. The chronic infection was also unchanged through an experimental mid-lactation treatment with pegylated granulocyte-colony stimulating factor (PEG-gCSF) and an additional periparturient treatment with PEG-gCSF. We isolated milk neutrophils from 1428 and compared them to two cows challenged with experimental S. aureus, strain Newbould 305. Neutrophils from 1428’s milk had higher surface expression of myeloperoxidase compared to experimental Newbould challenged animals, as well as increased presence of Neutrophil Extracellular Traps. This suggests a heightened activation state of neutrophils sourced from 1428’s naturally occurring infection. Upon postmortem examination, the affected quarter revealed multifocal abscesses separated by fibrous connective tissues. Abscesses were most common in the gland cistern and collecting duct region. Microscopically, the inflammatory reaction was pyogranulomatous to granulomatous and consistent with botryomycosis. Colonies of Gram-positive cocci were found within the eosinophilic matrix of the Splendore-Hoeppli reaction within granulomas and intracellularly within the acinar epithelium. Conclusions Collectively, we describe a unique case of chronic mastitis, the characterization of which provides valuable insight into the mechanics of S. aureus treatment resistance and immune escape.
Collapse
Affiliation(s)
- Ellie J Putz
- USDA-ARS-National Animal Disease Center, Infectious Bacterial Diseases Research Unit, Ames, IA, USA.,USDA-ARS-National Animal Disease Center, Ruminant Disease and Immunology Research Unit, Ames, IA, USA
| | - Mitchell V Palmer
- USDA-ARS-National Animal Disease Center, Infectious Bacterial Diseases Research Unit, Ames, IA, USA
| | - Hao Ma
- USDA-ARS-National Animal Disease Center, Ruminant Disease and Immunology Research Unit, Ames, IA, USA
| | - Eduardo Casas
- USDA-ARS-National Animal Disease Center, Ruminant Disease and Immunology Research Unit, Ames, IA, USA
| | - Timothy A Reinhardt
- USDA-ARS-National Animal Disease Center, Ruminant Disease and Immunology Research Unit, Ames, IA, USA
| | - John D Lippolis
- USDA-ARS-National Animal Disease Center, Ruminant Disease and Immunology Research Unit, Ames, IA, USA.
| |
Collapse
|
13
|
Pegbovigrastim Treatment around Parturition Enhances Postpartum Immune Response Gene Network Expression of whole Blood Leukocytes in Holstein and Simmental Cows. Animals (Basel) 2020; 10:ani10040621. [PMID: 32260288 PMCID: PMC7222845 DOI: 10.3390/ani10040621] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Accepted: 04/02/2020] [Indexed: 12/19/2022] Open
Abstract
Simple Summary The innate and adaptive immune system of dairy cows is impaired during the transition period, leading to an increase in susceptibility to infectious disease. Pegbovigrastim is a recombinant form of a granulocyte colony-stimulating factor that stimulates differentiation of hemopoietic stem cells to granulocytes and shortens maturation time within the bone marrow and release in circulation. The objective of the present study was to explore the effect of pegbovigrastim on whole blood leukocytes by analyzing the expression of 34 genes involved in immune and inflammatory responses immediately after calving in Simmental, a dual-purpose cow breed selected for both meat and milk production, and Holstein, a cow breed highly specialized for milk production. This study provides insight into immune cell functions impacted by pegbovigrastim treatment. Treatment of cows with pegbovigrastim increased the mRNA abundance level of most genes investigated, suggesting a thorough activation of the immune machinery during the critical post-partum period. Abstract Pegbovigrastim is a commercial long-acting analog of bovine granulocyte colony-stimulating factor (rbG-CSF) that promotes the increased count and functionality of polymorphonuclear cells in dairy cows around the time of parturition. We hypothesized that pegbovigrastim administered to periparturient cows at approximately seven days before parturition and within 24 hours after calving could affect the profiles of gene networks involved in leukocyte function. Blood was collected on Day 3 after calving from treated groups (pegbovigrastim (PEG); 13 Simmental (seven multiparous and six primiparous) and 13 Holstein (seven multiparous and six primiparous) cows) that received pegbovigrastim (Imrestor; Elanco Animal Health) and controls (CTR; 13 Simmental (seven multiparous and six primiparous) and 13 Holstein (six multiparous and seven primiparous) cows) that received saline solution. Blood from all cows was sampled from the jugular vein in a PAXgene Blood RNA System tube (Preanalytix, Hombrechtikon, Switzerland) for RNA extraction. The RT-qPCR analysis was performed to investigate a panel of 34 genes of interest, representing recognition, immune mediation, migration, cell adhesion, antimicrobial strategies, inflammatory cascade, oxidative pattern, and leukotrienes in whole blood leukocytes. Normalized data were subjected to the MIXED model of SAS (ver. 9.4) with treatment, breed, parity, and their interaction as fixed effects. Compared with CTR, whole blood leukocytes of PEG cows had higher expression of genes involved in recognition and immune modulation (CD14, CD16, MYD88, TLR2, and TLR4), cell adhesion (ITGB2, ITGAL, TLN1, SELL, SELPLG, and CD44), antimicrobial activity (MMP9, LTF, and LCN2), and inflammatory cascade (CASP1, TNFRSF1A, IL1B, IL1R, IL18, IRAK1, NLRP3, and S100A8). This suggested an improvement of migration, adhesion, and antimicrobial ability and an enhanced inflammatory response, which in turn could trigger immune cell activation and enhance function. Expression of SOD2 and ALOX5 was also greater in the PEG group. In contrast, compared with CTR cows, PEG led to lower expression of RPL13A, ALOX15, IL8, and TNF. Overall, leukocytes from Simmental compared with Holstein cows had greater expression of IDO1, RPL13A, ALOX5, CD44, CX3CR1, ITGB2, and TNFA, whereas expression of CD16 and TLR2 was lower. Overall, compared with multiparous cows, primiparous cows had higher expression of IL1B, IL18, MYD88, SELL, and TLR2 and lower expression of MMP9. Simmental cows seemed more sensitive to induction of the immune system after calving, as revealed by the greater abundance of genes involved in immune system adaptation, regardless of pegbovigrastim treatment. Primiparous cows undergoing a new stress condition with respect to older cows were characterized by leukocytes with a higher inflammatory response. In conclusion, pegbovigrastim led to higher expression levels of most genes involved in the processes investigated, suggesting a thorough activation of the immune machinery during the critical post-partum period.
Collapse
|
14
|
Roach HB, Brester JL, Abuelo A. Short communication: Effect of granulocyte-macrophage colony-stimulating factor on neonatal calf peripheral blood neutrophil function in vitro. J Dairy Sci 2019; 103:864-870. [PMID: 31733852 DOI: 10.3168/jds.2019-17441] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Accepted: 09/13/2019] [Indexed: 11/19/2022]
Abstract
Neutrophils are innate immunity cells that represent the first line of cellular defense against invading pathogens. Dairy calves, however, experience neutrophil dysfunction during the first weeks of age, contributing to increased disease susceptibility during this period. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that improves neutrophil function in neonates of other species and mature cows. However, its capability to improve neonatal calf neutrophil function is unknown. Therefore, our objective was to evaluate the effect of GM-CSF on the functional capabilities of neutrophils of neonatal calves in vitro. We hypothesized that supplementation of neonatal neutrophils with GM-CSF would increase microbicidal functions to levels comparable with those of mature immunocompetent cattle. For this, we isolated blood neutrophils from 12 healthy 2- to 3-d-old Holstein calves, and neutrophils from 6 mid-lactation Holstein cows were used as a reference of robust neutrophil function. Subsequently, neutrophils from both calves and cattle were incubated for 9 h with 4 concentrations (0, 0.005, 0.05, or 0.5 µg/mL) of GM-CSF, and microbicidal function of neutrophils was assessed in terms of phagocytosis, respiratory burst, myeloperoxidase (MPO) activity, and extracellular trap formation. Mixed models with Tukey pairwise comparisons were used to identify differences among treatment and age groups. Supplementation of GM-CSF in vitro increased phagocytosis and MPO activity of calf and cow neutrophils, although not in a concentration-dependent manner. Respiratory burst and extracellular trap formation were not affected by GM-CSF supplementation. All the microbicidal capacity functions assessed were lower in neutrophils from calves, but supplementation with GM-CSF increased phagocytosis and MPO activity of calf neutrophils to levels comparable with unsupplemented cow neutrophils. Collectively, our results demonstrated that in vitro supplementation of calf neutrophils with GM-CSF enhanced some functional microbicidal capabilities to levels comparable with immunocompetent cattle. Hence, it may be possible to augment the functional capacity of calf neutrophils in vivo through the therapeutic application of GM-CSF and consequently enhance calves' resistance to infections. This should be tested in future in vivo studies.
Collapse
Affiliation(s)
- Harry B Roach
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824
| | - Jill L Brester
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824
| | - Angel Abuelo
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824.
| |
Collapse
|
15
|
Putz EJ, Eder JM, Reinhardt TA, Sacco RE, Casas E, Lippolis JD. Differential phenotype of immune cells in blood and milk following pegylated granulocyte colony-stimulating factor therapy during a chronic Staphylococcus aureus infection in lactating Holsteins. J Dairy Sci 2019; 102:9268-9284. [PMID: 31400902 DOI: 10.3168/jds.2019-16448] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Accepted: 06/10/2019] [Indexed: 01/23/2023]
Abstract
Neutrophils are principal host innate immune cell responders to mastitis infections. Thus, therapies have been developed that target neutrophil expansion. This includes the neutrophil-stimulating cytokine granulocyte colony-stimulating factor (gCSF). Pegylated gCSF (PEG-gCSF; Imrestor, Elanco Animal Health, Greenfield, IN) has been shown to reduce the natural incidence of mastitis in periparturient cows in commercial settings and reduce severity of disease against experimental mastitis challenge. Pegylated gCSF stimulates neutrophil expansion but also induces changes in monocyte and lymphocyte circulating numbers, surface protein expression changes, or both. We hypothesized that PEG-gCSF modulates surface expression of monocytes and neutrophils and facilitates their migration to the mammary gland. We challenged 8 mid-lactation Holsteins with approximately 150 cfu of Staphylococcus aureus (Newbould 305) in a single quarter via intramammary infusion. All animals developed chronic infections as assessed by bacteria counts and somatic cell counts (SCC). Ten to 16 wk postchallenge, 4 of the animals were treated with 2 subcutaneous injections of PEG-gCSF 7 d apart. Complete blood counts, SCC, bacterial counts, milk yield, feed intake, neutrophils extracellular trap analysis, and flow cytometric analyses of milk and blood samples were performed at indicated time points for 14 d after the first PEG-gCSF injection. The PEG-gCSF-treated cows had significantly increased numbers of blood neutrophils and lymphocytes compared with control cows. Flow cytometric analyses revealed increased surface expression of myeloperoxidase (MPO) on neutrophils and macrophages in milk but not in blood of treated cows. Neutrophils isolated from blood of PEG-gCSF-treated cows had decreased surface expression of CD62L (L-selectin) in blood, consistent with cell activation. Surprisingly, CD62L cell surface expression was increased on neutrophils and macrophages sourced from milk from treated animals compared with cells isolated from controls. The PEG-gCSF-treated cows did not clear the S. aureus infection, nor did they significantly differ in SCC from controls. These findings provide evidence that PEG-gCSF therapy modifies cell surface expression of neutrophils and monocytes. However, although surface MPO+ cells accumulate in the mammary gland, the lack of bacterial control from these milk-derived cells suggests an incomplete role for PEG-gCSF treatment against chronic S. aureus infection and possibly chronic mammary infections in general.
Collapse
Affiliation(s)
- E J Putz
- Ruminant Diseases and Immunology Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, IA 50010; Oak Ridge Institute for Science and Education, Oak Ridge Associated Universities, Oak Ridge, TN 37830
| | - J M Eder
- Ruminant Diseases and Immunology Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, IA 50010; Immunobiology Interdepartmental Graduate Program, Iowa State University, Ames 50011
| | - T A Reinhardt
- Ruminant Diseases and Immunology Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, IA 50010
| | - R E Sacco
- Ruminant Diseases and Immunology Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, IA 50010; Immunobiology Interdepartmental Graduate Program, Iowa State University, Ames 50011
| | - E Casas
- Ruminant Diseases and Immunology Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, IA 50010
| | - J D Lippolis
- Ruminant Diseases and Immunology Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, IA 50010.
| |
Collapse
|
16
|
Tombácz K, Peters LM, Chang YM, Steele M, Werling D, Gibson AJ. Short communication: Pegbovigrastim treatment in vivo does not affect granulocyte ability to migrate to endometrial cells and kill bacteria in vitro in healthy cows. J Dairy Sci 2019; 102:9389-9395. [PMID: 31326166 DOI: 10.3168/jds.2019-16563] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 05/20/2019] [Indexed: 12/18/2022]
Abstract
In periparturient dairy cows, immune suppression, resulting in decreased neutrophil numbers and function, leads to increased susceptibility to postpartum conditions such as mastitis, retained placenta, and metritis. Administration of polyethylene glycol-conjugated bovine granulocyte colony stimulating factor (pegbovigrastim, Imrestor; Elanco Animal Health, Greenfield, IN) 7 d before and within 24 h of calving, effectively improves granulocyte production and function in vivo as well as in milk. A recently developed coculture assay was adapted for use with endometrial epithelial cells to assess the effects of pegbovigrastim application on directed granulocyte migration and bactericidal activity in vitro on a per-cell basis in endometrial cell cultures. Granulocytes from treated and untreated periparturient cows (6 and 5 per group, respectively) were evaluated for their ability to migrate to and kill bacteria after treatment, in context of the infected endometrium. We hypothesized that in addition to increasing the absolute concentration of circulating neutrophil granulocytes, pegbovigrastim treatment in vivo alters the ability of granulocytes to migrate to endometrial cells in vitro. The results clearly show a marked increase in the total concentration of granulocytes and monocytes between the 2 treatment groups as early as 2 d after the first injection, and this increased between the samples taken 2 d after calving. No migratory or killing differences were identified between granulocytes of both groups, suggesting that pegbovigrastim-induced granulocytes were as effective as non-induced cells. This may also be due to the absence of negative energy balance in the study animals and leads us to conclude that the positive effects seen in vivo are most likely based on the larger number of granulocytes present rather than a direct effect of pegbovigrastim treatment on the functionality of cells for the parameters tested in this study.
Collapse
Affiliation(s)
- K Tombácz
- Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, AL9 7TA, United Kingdom
| | - L M Peters
- Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, AL9 7TA, United Kingdom
| | - Y-M Chang
- Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, AL9 7TA, United Kingdom
| | - M Steele
- Elanco Animal Health, Eli Lilly and Company Ltd., Basingstoke, RG24 9NL, United Kingdom
| | - D Werling
- Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, AL9 7TA, United Kingdom.
| | - A J Gibson
- Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, AL9 7TA, United Kingdom
| |
Collapse
|
17
|
Lippolis J, Powell E, Reinhardt T, Thacker T, Casas E. Symposium review: Omics in dairy and animal science—Promise, potential, and pitfalls. J Dairy Sci 2019; 102:4741-4754. [DOI: 10.3168/jds.2018-15267] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Accepted: 08/06/2018] [Indexed: 01/08/2023]
|